Coronary Artery Bypass Graft Market - By Method (Traditional (On-pump), Minimally Invasive Direct [Keyhole, Off-pump]), Surgery Type (Single, Double, Triple, Quadruple), Product (Grafts, Retractors, Heart Positioner), End-use – Global Forecast 2024 – 2032

Coronary Artery Bypass Graft Market Size

Coronary Artery Bypass Graft Market size was valued at around USD 13.9 billion in 2023 and is anticipated to register a CAGR of 6.8% between 2024 and 2032. Coronary artery bypass graft (CABG) surgery is a medical procedure performed to treat coronary artery disease (CAD). During this surgical intervention, a surgeon creates new pathways for blood flow to the heart muscle by bypassing narrowed or blocked coronary arteries using grafts.
 

These grafts are segments of veins or arteries harvested from other parts of the patient's body, such as the leg or chest. By creating these bypasses, CABG surgery restores adequate blood supply to the heart, alleviating symptoms such as chest pain and reducing the risk of heart attack.
 

The increasing prevalence of cardiovascular disease has emerged as a significant driver for the market. For instance, according to the World Heart Federation (WHF), in 2021 an estimated 20.5 million people lost their lives due to cardiovascular diseases (CVDs). Therefore, there is a rising need for innovative approaches and technologies in the management and treatment of cardiovascular diseases (CVDs), particularly in aspects such as early detection, personalized medicine, minimally invasive procedures, and post-surgical care. These advancements aim to improve patient outcomes and reduce the burden of CVDs on global health.
 

Furthermore, the growing elderly population, advancements in technology, increasing prevalence of hypertension, and favorable reimbursement scenarios, among other contributing factors, stimulate the demand for the market.
 

Coronary Artery Bypass Graft Market Trends

Technological advancements in CABG procedures have revolutionized the landscape of cardiovascular surgery, offering innovative solutions to address the complex challenges associated with coronary artery disease (CAD) and other cardiovascular conditions.
 

• These advancements include the adoption of minimally invasive techniques, such as robotic-assisted surgery and endoscopy, which are estimated to reach USD 72 billion by 2032. These approaches result in reduced trauma, shorter recovery times, and improved patient outcomes.
   
• Further, robotic medical imaging systems allow surgeons to perform CABG procedures with enhanced precision and dexterity. These systems provide a three-dimensional view of the surgical field, along with instruments that can rotate and bend with greater flexibility than the human hand.
   
• Moreover, innovations in imaging technologies, such as intraoperative angiography and three-dimensional imaging, enable surgeons to visualize coronary arteries and cardiac structures with exceptional detail during CABG procedures.
   

Coronary Artery Bypass Graft Market Analysis

The market is segmented based on method into traditional (on-pump) CABG and minimally invasive direct CABG. Additionally, the minimally invasive direct CABG segment is further divided into off-pump CABG, keyhole CABG, and other minimally invasive CABG surgery types. It is estimated that the minimally invasive direct CABG segment will account for USD 16.8 billion by 2032.
 

• Minimally invasive direct coronary artery bypass (MIDCAB) surgery represents a significant advancement in cardiac surgery, offering patients a less invasive alternative to traditional CABG procedures.
   
• In MIDCAB, a smaller incision is made on the left side of the chest, typically between the ribs, unlike the sternotomy approach used in traditional CABG. This approach minimizes surgical trauma, decreases tissue damage, and reduces blood loss, ultimately enhancing operational efficiency and optimizing patient outcomes.
   
• Moreover, MIDCAB surgery is commonly performed without the use of  cardiopulmonary bypass pumps, reducing the likelihood of complications such as systemic inflammation, neurocognitive dysfunction, and bleeding risk typically associated with this method. This aspect contributes to the propulsion of segment growth.
   

Based on surgery type, the coronary artery bypass graft market is segmented into single CABG surgery, double CABG surgery, triple CABG surgery, and quadruple CABG surgery. The triple CABG surgery segment accounted for USD 4.8 billion in 2023.
 

• Triple CABG surgery enables the simultaneous bypassing of three coronary arteries with significant blockages. This comprehensive revascularization ensures the restoration of blood flow to the heart muscle, reducing the risk of myocardial infarction and improving overall cardiac function.
   
• Moreover, triple CABG surgery effectively alleviates symptoms of severe coronary artery disease, such as chest pain and shortness of breath, by restoring blood flow to the affected areas of the heart.
   
• Additionally, triple CABG surgery provides comprehensive revascularization, symptom relief, and long-term survival benefits for patients with multi-vessel coronary artery disease, making it an effective treatment option in the management of coronary artery disease and augmenting the segment growth of the market.
   

Based on product, the coronary artery bypass graft market is segmented into grafts, retractors, heart positioners, tissue stabilizers, and other products. The grafts segment is estimated to account for USD 12.1 billion revenue size by 2032.
 

• Grafts, sourced from alternative blood vessels within the body, serve as conduits to bypass blockages in the coronary arteries. By establishing alternate routes for blood circulation, grafts replenish sufficient perfusion to the heart muscle, thereby alleviating symptoms like chest pain and enhancing overall cardiac performance.
   
• Furthermore, grafts provide a durable solution for coronary artery disease by bypassing blocked or narrowed arteries, unlike some other interventions that may require frequent monitoring or repeat procedures.
   
• Moreover, grafts are essential components of CABG surgery, providing a durable and effective solution for restoring blood flow to the heart muscle and alleviating symptoms of coronary artery disease. Thus, all these factors contribute to the escalation of segment growth.
   

Based on end-use, the coronary artery bypass graft market is segmented into hospitals, cardiology centres, and other end-users. The hospitals segment estimated to account for USD 10.2 billion revenue size by 2032.
 

• Hospitals invest in state-of-the-art cardiac catheterization labs, operating rooms, and intensive care units (ICUs) equipped with advanced monitoring and imaging technology.
   
• Furthermore, hospitals with dedicated cardiac surgery programs often boast highly skilled cardiac surgeons, anesthesiologists, and support staff who specialize in performing CABG surgeries.
   
• Thus, hospitals provide comprehensive postoperative care and rehabilitation for CABG patients. This includes ICU monitoring, pain management, complication management, and cardiac rehabilitation services aimed at facilitating physical recovery and lifestyle adjustments, thereby contributing to the growth of the market.
   

In 2023, North America held a significant market share of 40.5% in the coronary artery bypass graft market and is predicted to witness substantial market growth over the analysis timeline.
 

• The region's innovation in cardiovascular medicine drives ongoing research efforts aimed at developing novel surgical techniques, enhancing perioperative care, and introducing innovative technologies to optimize outcomes in coronary artery bypass graft surgery.
   
• The rising mortality rates associated with cardiovascular diseases are expected to contribute to an increased utilization of CABG surgical procedures. According to historical data from 2021 provided by the Centers for Disease Control and Prevention (CDC), approximately 695,000 individuals in the U.S. succumbed to heart disease.
   
• Additionally, North America boasts advanced healthcare infrastructure, including state-of-the-art hospitals, specialized cardiac centers, and cutting-edge medical technology. This infrastructure facilitates the delivery of high-quality cardiac care.
   

Coronary Artery Bypass Graft Market Share

The coronary artery bypass graft industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Coronary Artery Bypass Graft Market Companies

Some of the eminent market participants operating in the coronary artery bypass graft industry include:

• Edwards Lifesciences Corporation
• Getinge AB
• Genesee Biomedical
• Guidant Corporation
• LivaNova PLC
• Medtronic plc
• Novadaq Technologies Inc.
• Stryker Corporation
• Teleflex Incorporated
• Terumo Corporation
                   

Coronary Artery Bypass Graft Industry News:

• In August 2022, Medtronic plc completed the acquisition of Affera, Inc. This acquisition expanded the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform. The platform comprises a unique, fully integrated diagnostic, focal pulsed field, and radiofrequency ablation solution.
   

The coronary artery bypass graft market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Method

• Traditional (on-pump) CABG                  
• Minimally invasive direct CABG
  • Off-pump CABG                                    
  • Keyhole CABG                                       
  • Other minimally invasive CABG surgery types

Market, By Surgery Type

• Single CABG surgery         
• Double CABG surgery                  
• Triple CABG surgery          
• Quadruple CABG surgery

Market, By Product

• Grafts
  • Saphenous vein grafts                           
  • Internal thoracic artery grafts      
  • Other grafts
• Retractors
• Heart positioners     
• Tissue stabilizers
• Other products       

Market, By End-Use

• Hospitals
• Cardiology centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa